Intestinal Cancer Can be Cured

Aug 14, 2011 by Alexander

Intestinal Cancer can be cured, even on advanced level.

Colorectal cancer liver metastases still have a chance of cure

Clinical data show that more than 50% of colorectal cancer liver metastases will appear, of which about 25% of the new issue of liver metastases of colorectal cancer with the same time. Newly diagnosed patients with liver metastases in only 20% of the possibility of radical surgery, while the vast majority of patients with liver metastases can not get radical resection. Sun Yat-sen University Cancer Hospital, vice president Professor Xu Ruihua that patients with resectable colorectal cancer liver metastases median survival of approximately 35 months, 5-year survival rate of about 30 to 50%.Those patients with unresectable liver metastases the prognosis is much worse, so they should take positive and scientific treatment, for the original unresectable lesions into resectable liver metastases, the maximum extent possible to improve the therapeutic effect.
Beijing Cancer Hospital, vice president, Chinese Medical Association tumor credits will be chairman Professor Gu Jin further pointed out that untreated patients with colorectal liver metastases the median survival is only 6 to 12 months, liver metastases receiving chemotherapy alone in thosemedian survival of 12 to 24 months, a handful of survival to more than five years. The surgery can cure patients with liver metastases 5-year survival rate can reach 35% to 58%.

Therefore, patients with unresectable liver metastases should be a new adjuvant therapy, given that drug treatment before surgery or radiotherapy, so that tumor tissue can be reduced to the extent of surgery, and then to radical resection surgery. And chemotherapy with Erbitux as the representative of molecular targeted drugs can significantly improve the rate of response to chemotherapy and liver resection rate, reduced tumor volume, improve patient quality of life and prolong survival time. Two recent studies have shown that targeted therapy added to make about 34% and 58% of patients were converted to resectable.
This means that this part of the liver metastases in patients with advanced into resectable, the median survival time has increased 2-3 times, life will regain hope. Experts also advise, defined as recurrent or metastatic colorectal cancer should be detected K-ras gene status; for patients with KRAS wild-type Erbitux combined with standard chemotherapy treatment, patients can obtain a satisfactory prognostic Liu Cheng effect.

Standard treatment and multidisciplinary collaboration to ensure treatment

It can be seen, after colorectal cancer liver metastases occur, patients still have access to the chance of cure, but many patients did not achieve clinically satisfactory treatment, there are two main reasons, one is not strictly standardized treatment, the other is all direct multi-disciplinary cooperation department has not been done, such as colorectal cancer liver metastases in patients with medical need for new adjuvant therapy, and surgery requires surgeons, while the timing of surgery requires timely communication within the surgeon to decide.

Standardization of treatment is the most basic requirements in accordance with guidelines for treatment, including diagnostic standardization, standardization of treatment planning, implementation plan and other aspects of standardization, and there are many aspects of clinical not strictly enforced, such as chemotherapy, due to various doses on reason for not using enough, and ultimately affect patient outcomes.
Shanghai Cancer Hospital, Fudan University Professor Cai Sanjun that hospital for many years through our multi-disciplinary collaboration of the situation, on the one hand doctors of knowledge is so rich, more importantly, the idea is to standard treatment deeply rooted, well train young doctors, ultimately improving the treatment of colorectal cancer, to enable patients to benefit.
Professor Cai Sanjun further pointed out: At present, the treatment of colorectal cancer in our country the concept of the biggest changes from the multi-disciplinary surgical treatment to standard treatment, the various departments for patients with doctors to develop the overall treatment plan. For example, patients with colorectal liver metastases, tumors of advanced medical treatment by surgery will not be converted to resectable colorectal liver lesions lesions, so as to achieve the purpose of cure, so patients with long-term survival.

NECTAR project to provide support for the standard treatment

Asia-Pacific colorectal colorectal cancer multi-disciplinary (NECTAR) first summit recently held in Hangzhou, China, the first summit brought together officials from the Asia-Pacific region and Europe’s leading oncology experts, but also marks the Asia-Pacific multi-disciplinary networks. The network aims to promote a timely manner for patients with metastatic colorectal cancer multidisciplinary treatment philosophy and methods, particularly for patients with colorectal liver metastases to bring hope of cure, with a milestone.
Merck Serono Oncology Business Unit, Asia Pacific head of MS Ee Boon Huey said, NECTAR project provides an exciting opportunity, in accordance with best international standards and strategies for developing new treatments best treatment for colorectal cancer paths and methods for patients throughout the region to bring curable effect. The tumor from Europe’s top scholars and institutions with the Asia-Pacific countries at the forefront of cancer research institutions to establish strong partnerships, but also makes the achievement of the goals become more realistic.
“NECTAR project to establish the region of clinicians to provide patients with personalized treatment paved the way for novel targeted therapies such as Erbitux (cetuximab) able to target specific types of disease, and the types of patients bring hope and healing better chance of survival. “Chinese Anti-Cancer Association, the professional committee chairman of colorectal cancer.

NECTAR project is the first Asian colorectal liver metastases platform for multidisciplinary treatment, but also with European experts in the Asia-Pacific counterparts are exchanging experiences and sharing platform. First summit of the countries and regions from around the world leader Oncology gathered together for all participants to determine the specific clinical treatment programs and strategies, and has established metastatic colorectal cancer to improve the efficacy of multidisciplinary collaborative clinical example.